Lakefront Biotherapeutics (LKFT) Cash from Operations (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Cash from Operations for 10 consecutive years, with 107664129.51 the latest figure, recorded in Q1 2026.

• Quarterly Cash from Operations fell 120.09% year-over-year to 107664129.51 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 354011884.0 (up 17.21% YoY) and the FY2025 annual result came in at 350377258.06, up 26.21% from the prior year.
• Cash from Operations fell to 107664129.51 in Q1 2026 per LKFT's latest filing, from 86743978.19 in the prior quarter.
• Over the last five years, Cash from Operations for LKFT reached as high as 48918378.21 in Q1 2025 and fell as low as 204674731.13 in Q4 2022.
• A 5-year average of 111968378.32 and a median of 110489669.96 in 2023 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2025 — Cash from Operations surged 68.09% — and 2026, when it sank 120.09%.
• Year by year, Cash from Operations stood at 204674731.13 in 2022, then surged by 43.95% to 114725135.76 in 2023, then gained by 3.52% to 110685398.1 in 2024, then gained by 21.63% to 86743978.19 in 2025, then slipped by 24.12% to 107664129.51 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 107664129.51, 86743978.19, and 48918378.21 for Q1 2026, Q4 2025, and Q1 2025 respectively.